NeuroNEXT Network

Standard Operating Procedure (SOP)

Creating, Verifying, Implementing, and Archiving a Randomization Sequence or Algorithm

Version 3.0

SOP NN BIO 903

Originators: NeuroNEXT CCC and DCC Personnel

Signature and Date: DocuSigned by Christopher Coffey Christopher Coffey | I approve this document 17-Feb-2023 | 3:52:59 PM PST C68AC8DD80334CF982AED1200765F147 17-Feb-2023
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)
Signature and Date: DocuSigned by Merit Cudkowicz Merit Cudkowicz | I approve this document 17-Feb-2023 | 8:26:42 AM EST 9F8FE4180E504C6AB0A67B835E80C644 17-Feb-2023
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)
Signature and Date: DocuSigned by Marianne Chase Marianne Chase | I approve this document 17-Feb-2023 | 1:32:40 PM EST 58FE690F6BCA4F2390E3DA15BCE3F578 17-Feb-2023
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

Signature and Date:

DocuSigned by DIXIE ECKLUND

I approve this document
17-Feb-2023 | 4:11:52 PM PST

7006AF622EFC40B6A067A08EC02591B6

17-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Director of Operations)

Signature and Date:

DocuSigned by Stacey Grabert

I approve this document
22-Feb-2023 | 11:12:01 AM EST

60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon

I approve this document
21-Feb-2023 | 6:40:36 AM PST

72C6AAFD8CC4485582ACA0700072901A

21-Feb-2023

Name and Title: Joan Ohayon, RN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

NN BIO 903

NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR CREATING, VERIFYING, IMPLEMENTING, AND ARCHIVING A RANDOMIZATION SEQUENCE OR ALGORITHM

1. POLICY

Randomization assignment systems for all NeuroNEXT clinical trials will be developed, verified, implemented, and archived at the NeuroNEXT Data Coordinating Center (DCC). Depending on the type of trial and the requirements of the protocol, a fixed randomization sequence or adaptive randomization algorithm will be created.

The Lead Biostatistician will collaborate with the DCC PI and the Protocol Principal Investigator (PPI) to define parameters to be considered during development of the randomization sequence or algorithm. DCC Biostatisticians will then generate a brief randomization plan for the trial based on the parameters that were agreed upon during the protocol design phase. If appropriate for the project, a Biostatistician who is external to the DCC may participate in developing the assignment system and generating the randomization plan. The plan will be approved by the DCC PI, the PPI, and the External Biostatistician (if applicable) before the assignment system is created.

Clinical Study Sites (CSS) will randomize subjects through the electronic data capture (EDC) system. If the system is temporarily unavailable at the time of randomization, the CSS will follow a backup procedure that has been established and approved by the PPI and the DCC PI.

This SOP describes general procedures for:

- defining a fixed randomization strategy or adaptive randomization algorithm;
- creating, verifying, and implementing the randomization sequence;
- CSS subject randomization and access to the randomization sequence if the electronic data capture system is temporarily unavailable at the time of randomization; and
- documenting and archiving the randomization sequence.

The final randomization sequence or algorithm will be signature-approved by the DCC PI, the DCC Lead Biostatistician, and the External Biostatistician (if applicable).

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 1996 ICH E6 Consolidated Guidance. The policies and procedures described in this SOP apply to the NeuroNEXT Clinical Coordinating Center (CCC) and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, External Biostatisticians (if applicable), or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

The DCC is responsible for adhering to the procedures outlined in this SOP. The DCC PI, the Independent Biostatisticians, and the Information Technology Lead have general responsibility for creating, implementing, and maintaining fixed randomization sequences and adaptive randomization algorithms. The DCC Independent Biostatisticians are responsible for consulting with the DCC PI, the PPI, and the External Biostatistician (if applicable) during the development of the randomization sequence or algorithm for each study.

4. APPLICABLE REGULATIONS AND GUIDELINES

ICH E6, 4.5	Compliance with Protocol
ICH E6, 4.9	Records and Reports
ICH E6, 5.1	Quality Assurance and Quality Control
ICH E6, 5.4	Trial Design

ICH E6, 5.5	Trial Management, Data Handling and Record Keeping
ICH E6, 5.23	Multicenter Trials
ICH E6, 6.0	Clinical Trial Protocol and Protocol Amendment(s)
ICH E8	General Considerations for Clinical Trials (December 1997)
ICH E9	Statistical Principles for Clinical Trials (September 1998)
ICH E10	Choice of Control Group and Related Issues in Clinical Trials (May 2001)

5. REFERENCES TO OTHER APPLICABLE SOPS

NN BIO 901	Working with an External Biostatistician
NN BIO 902	Statistical Analysis Plan Development

6. ATTACHMENTS AND REFERENCES

NN BIO 903 – A	Document History
NN BIO 903 – B	Randomization Sequence Signature Page
NN BIO 903 – C	Randomization Algorithm Signature Page

Design and Analysis of Clinical Trials (Wiley Series in Probability and Statistics): Concepts and Methodologies. Chow, Shein-Chung Liu, Jen-Pei, John Wiley and Sons, Inc. 2003

Clinical Trials: A Methodologic Perspective (Wiley Series in Probability and Statistics). Piantadosi, Steven, John Wiley and Sons, Inc. 1997

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

Adaptive Randomization Sequence	A randomization sequence in which the probability of assignment of a subject to each treatment group depends either on observations made to subjects previously enrolled, or on the distribution of baseline covariates. As a result, the assignment of subjects to treatment groups cannot be defined in advance
CCC	Clinical Coordinating Center at Massachusetts General Hospital
CSS	Clinical Study Site(s)
DCC	Data Coordinating Center at The University of Iowa
DM	Data Management
DM Lead	Leader of the Data Management team at the DCC
External Biostatistician	A Biostatistician who is not a member of the DCC Biostatistics Team. An External Biostatistician may act as a Study Biostatistician for a study.
Fixed Randomization Sequence	A randomization sequence in which the assignment of subjects to treatment groups can be defined in advance. This will generally be defined in the study protocol, including any blocking or stratification strategies. As subjects enroll in the study, they will be assigned to treatment group according to the randomization sequence (i.e., the first enrolled subject will be assigned to the first treatment listed on the randomization sequence, the second subject enrolled will be assigned to the second treatment listed in the randomization sequence, and so on).

IT	Information Technology
IT Lead	Leader of the Information Technology team at the DCC
Independent Biostatisticians	Unblinded Biostatisticians for a study. Typically, at least two Independent Biostatisticians will be assigned to each study.
NINDS	National Institute of Neurological Disorders and Stroke
PPI	Protocol Principal Investigator
QA	Quality Assurance
QA Officer	Quality Assurance officer for a study
Randomization Plan	This document describes the overall plan for implementing a randomization for a protocol, and includes the plan for generating the randomization sequence for a fixed randomization, or creating and implementing rules for an adaptive randomization.
Study Biostatistician	Blinded Biostatistician for a study..

8. SPECIFIC PROCEDURES

A. Defining the Randomization and Creating a Randomization Plan

#	*Who*	*Task*	*Attachment/ Reference*	*Related SOP*
1.	DCC Independent Biostatisticians	Collaborate with the PPI, DCC PI, and the External Biostatistician (if applicable) to define parameters to be incorporated into a randomization plan for the protocol.		NN BIO 901
2.	DCC Independent Biostatisticians	Assign an Independent Biostatistician to prepare the randomization plan.		
3.	DCC Independent Biostatistician	Prepare a randomization plan that includes a written description of the randomization strategy or algorithm based on the randomization procedures stated in the study protocol. For a fixed randomization sequence, the randomization plan describes: • the method that will be used to generate the random treatment assignment • a back-up randomization procedure. For an adaptive randomization algorithm, the randomization plan describes: • the algorithm to be implemented • how the algorithm will be tested to ensure that it is working correctly before implementation • a back-up randomization strategy.		
4.	DCC PI, PPI, External Biostatistician (if applicable)	Review and approve the randomization plan.		NN BIO 901

#	Who	Task	Attachment/ Reference	Related SOP
5.	DCC Independent Biostatistician	After review and approval of the randomization plan, and prior to implementation, attach a version number and version date in the footer of the document.		

B. Creating, Verifying, and Implementing a Fixed Randomization Sequence

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC Independent Biostatisticians	Assign an Independent Biostatistician to generate the randomization sequence.		
2.	DCC Independent Biostatistician	Prior to enrollment of the first subject, prepare a randomized sequence of treatment assignments according to the procedure outlined in the randomization plan, the description in the study protocol, and the approved specifications. Include the following components in the randomized sequence: • an electronic file with the required randomization sequences, in a format agreed upon by the Lead Biostatistician and the leader of the information technology team; • a detailed description of the contents of the file, including column contents and all codes that were used; • a tabulation of the treatment assignment verifying that the appropriate blocking strategy has been used and an appropriate number of treatment assignments have been made in each block and for each stratum; • a listing of any computer program(s) used to generate the sequence.		
3.	DCC Independent Biostatistician	Review the electronic file visually, and by preparing appropriate tabulations, to verify that the randomization plan has been followed.		
4.	DCC Independent Biostatisticians	Review together any discrepancies that are found. The Study Biostatistician resolves any deviations from the randomization plan and repeats the verification.		
5.	DCC Independent Biostatistician	Once both statisticians agree that the randomization plan has been accurately executed, forward the electronic file to the Information Technology (IT) Lead.		
6.	DCC IT Lead	Enter randomization sequences into appropriate randomization table. Print the contents of the randomization table.		
7.	DCC Independent Biostatistician	Compare original randomization table to print-out from database to validate that randomization sequences have been properly inserted into database table.		

#	Who	Task	Attachment/ Reference	Related SOP
8.	DCC PI, DCC Independent Biostatisticians ; External Biostatistician (if applicable)	Review and signature-approve the final randomization sequence.	NN BIO 903 - B	

C. Creating, Verifying, and Implementing an Adaptive Randomization Algorithm

#	Who	Task	Attachment/ Reference	Related SOP
1.	DCC Independent Biostatisticians	Assign an Independent Biostatistician to create specifications for development of an algorithm for the adaptive randomization.		
2.	DCC Independent Biostatistician, DCC DM Team	Refer to the randomization plan to create specifications that include requirements for all rules that must be implemented for the adaptive randomization.		
3.	DCC Independent Biostatistician, DCC DM Team	Create a testing plan to validate the algorithm that contains testing conditions for all requirements in the specifications.		
4.	DCC Independent Biostatistician	Send the specifications and testing plan to the IT Lead for implementation.		
5.	DCC IT Lead	Develop and implement the randomization algorithm.		
6.	DCC Independent Biostatistician	Validate the requirements according to the testing plan.		
7.	DCC PI, DCC Independent Biostatistician; External Biostatistician (if applicable)	Review and signature-approve the final randomization algorithm.	NN BIO 903 - C	
8.	DCC Independent Biostatistician	Store the electronic files containing the algorithm in a secure and restricted area on the DCC shared drive.		

D. Clinical Study Site Randomization Procedures

#	*Who*	*Task*	*Attachment/ Reference*	*Related SOP*
1.	CSS	At the time of randomization of a study subject, complete the randomization process through the electronic data capture system.		
2.	Authorized CSS Personnel	If the electronic data capture system is temporarily unavailable at the time of the randomization, follow the backup procedures that have been developed and approved for the study.		
3.	Authorized CSS Personnel	Follow the procedure that has been developed regarding the final disposition of any backup randomization materials at the end of study.		

E. Documenting and Archiving the Randomization

#	*Who*	*Task*	*Attachment/ Reference*	*Related SOP*
1.	DCC Independent Biostatisticians and DCC IT Lead	Access to the electronic randomization sequences will be limited to the DCC PI, DCC Independent Biostatisticians and authorized DCC IT personnel.		
2.	DCC Independent Biostatistician, DCC IT Lead	Store the randomization plan and copies of the programs that were used to generate the randomization sequences or algorithm on a restricted area of the DCC shared drive. Access to these documents will be limited only to authorized personnel.		

DocuSign

Certificate Of Completion

Envelope Id: 1DC4038F53714E339F2186A80A7A7FC8 Status: Completed

Subject: Complete with DocuSign: NN BIO 903 Creating, Verifying, Implementing, and Archiving a Randomiza...

Source Envelope:

Document Pages: 8 Signatures: 6 Envelope Originator:

Certificate Pages: 6 Initials: 0 Tania Leeder

AutoNav: Enabled TLEEDER@PARTNERS.ORG

EnvelopeId Stamping: Disabled IP Address: 73.123.188.5

Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign

2/17/2023 8:17:08 AM TLEEDER@PARTNERS.ORG

Signer Events	Signature	Timestamp
Christopher Coffey christopher-coffey@uiowa.edu Security Level: Email, Account Authentication (Required), Login with SSO	 Signature Adoption: Pre-selected Style Signature ID: C68AC8DD-8033-4CF9-82AE-D1200765F147 Using IP Address: 128.255.113.139 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:19:33 AM Viewed: 2/17/2023 6:52:50 PM Signed: 2/17/2023 6:53:02 PM
Electronic Record and Signature Disclosure: Accepted: 2/17/2023 6:52:50 PM ID: eb31b996-d0a6-4482-8ffc-340c60d33915		
DIXIE ECKLUND dixie-ecklund@uiowa.edu Security Level: Email, Account Authentication (Required), Login with SSO	 Signature Adoption: Drawn on Device Signature ID: 7006AF62-2EFC-40B6-A067-A08EC02591B6 Using IP Address: 128.255.112.230 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:19:34 AM Viewed: 2/17/2023 7:10:56 PM Signed: 2/17/2023 7:11:55 PM
Electronic Record and Signature Disclosure: Accepted: 2/17/2023 7:10:56 PM ID: 744bd73c-d07e-465b-bd7d-f7040e06bc48		

Signer Events	Signature	Timestamp
Joan Ohayon ohayonj@ninds.nih.gov Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 72C6AAFD-8CC4-4855-82AC-A0700072901A Using IP Address: 156.40.137.188 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:19:36 AM Resent: 2/21/2023 8:25:41 AM Viewed: 2/21/2023 9:40:23 AM Signed: 2/21/2023 9:40:39 AM
Electronic Record and Signature Disclosure: Accepted: 2/13/2023 2:03:22 PM ID: 385a0a53-0f0c-4395-88f6-d5700c36e050		
Marianne Chase MCHASE@mgh.harvard.edu Sr Director, Clinical Trial Operations Insight OBO The Massachusetts General Hospital Security Level: Email, Account Authentication (Required), Logged in	 Signature Adoption: Pre-selected Style Signature ID: 58FE690F-6BCA-4F23-90E3-DA15BCE3F578 Using IP Address: 73.114.253.109 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:19:34 AM Viewed: 2/17/2023 1:32:18 PM Signed: 2/17/2023 1:32:46 PM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
Merit Cudkowicz cudkowicz.merit@mgh.harvard.edu Chief of Neurology Security Level: Email, Account Authentication (Required), Logged in	 DocuSigned by Merit Cudkowicz I approve this document 17-Feb-2023 | 8:26:42 AM EST 9F8FE4180E504C6AB0A67B835E80C644 Signature Adoption: Pre-selected Style Signature ID: 9F8FE418-0E50-4C6A-B0A6-7B835E80C644 Using IP Address: 68.239.56.73 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:19:35 AM Viewed: 2/17/2023 8:26:31 AM Signed: 2/17/2023 8:26:44 AM
Electronic Record and Signature Disclosure: Accepted: 2/17/2023 8:26:31 AM ID: afb45968-eb8a-48b1-9891-87d5b138c574		

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/17/2023 8:19:36 AM Resent: 2/21/2023 8:25:42 AM Viewed: 2/22/2023 11:11:49 AM Signed: 2/22/2023 11:12:03 AM
Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/17/2023 8:19:36 AM
Certified Delivered	Security Checked	2/22/2023 11:11:49 AM
Signing Complete	Security Checked	2/22/2023 11:12:03 AM
Completed	Security Checked	2/22/2023 11:12:03 AM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.